title: Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats.
abstract: Diabetic neuropathy is the most common chronic complication of diabetes. The aim of the present study was to evaluate the protective effects of curcumin against neuropathy in gliclazide-treated diabetic rats. Diabetes was induced by an intraperitoneal injection of streptozotocin (45 mg/kg). Diabetic animals were given gliclazide (10 mg/kg, orally) alone or combined with curcumin (100 mg/kg, orally) or gabapentin (30 mg/kg, intraperitoneally as a positive control). Behavioral responses to thermal (hot plate and tail flick) and mechanical (tail pinch) pain, and some biochemical tests (serum glucose, C-peptide, peroxynitrite, lipid peroxides, and tumor necrosis factor-α) were assessed after 5 consecutive weeks of daily treatment. Combined treatment of curcumin with gliclazide significantly increased hot-plate and tail-flick latencies in comparison with that of the diabetic control group. The threshold of mechanical hyperalgesia was also significantly elevated. Serum glucose and C-peptide levels were significantly increased in the combined treatment compared with the diabetic control group, whereas serum levels of peroxynitrite, lipid peroxide, and tumor necrosis factor-α production were significantly decreased. The data suggest that the combination of curcumin with gliclazide may protect against the development of diabetic neuropathy, with favorable effects with respect to the gliclazide/gabapentin combination.
authors.affiliation: Medicinal and Pharmaceutical Chemistry Department (Pharmacology group), National Research Center, Dokki, Egypt. hanan_naeim@yahoo.com
authors.forename: Hanan Naeim
authors.initials: HN
authors.lastname: Attia
authors.forename: Nouf Mohammed
authors.initials: NM
authors.lastname: Al-Rasheed
authors.forename: Nawal Mohammed
authors.initials: NM
authors.lastname: Al-Rasheed
authors.forename: Yousreya Ali
authors.initials: YA
authors.lastname: Maklad
authors.forename: Amany A E
authors.initials: AA
authors.lastname: Ahmed
authors.forename: Sanaa Abdel Baky
authors.initials: SA
authors.lastname: Kenawy
mesh_terms: D000588:Amines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D003929:Diabetic Neuropathies / Q000097:blood / Q000517:prevention & control*; D004359:Drug Therapy, Combination / Q000379:methods; D000077206:Gabapentin; D005907:Gliclazide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006930:Hyperalgesia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D017288:Pain Threshold / Q000187:drug effects; D030421:Peroxynitrous Acid / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D002096:C-Peptide; D003509:Cyclohexanecarboxylic Acids; D007004:Hypoglycemic Agents; D008054:Lipid Peroxides; D014409:Tumor Necrosis Factor-alpha; D030421:Peroxynitrous Acid; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D005907:Gliclazide; D003474:Curcumin